International Biopharmaceutical Company and

Leader in Canadian Medical Cannabis

March 2017

Herbal

bottles

2

Disclaimer

GENERAL

This documentation is a presentation of general background information about the activities of CanniMed Therapeutics Inc. (the “Company”, “CMED”, “us” or “we”). The information contained in this presentation is derived solely fromotherwise publicly available information concerning CMED and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in CMED.

This presentation does not constitute or form part of any offer or invitation for the sale or purchase of securities or any of the assets, business or undertaking described herein nor shall it or any part of it form the basis of or be relied onin connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this presentation who are considering acquiring securities of CMED are reminded that any such purchase or subscriptionmust not be made on the basis of the information contained in this presentation but are referred to the continuous disclosure documents of CMED filed on SEDAR at www.sedar.com. The contents of this presentation are not to beconstrued as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice.

No representation or warranty, express or implied, is made or given by or on behalf of CMED or any of its affiliates or subsidiary undertakings or any of the directors, officers or employees of any such entities as to the accuracy,completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this presentation, CMED does not undertakeor agree to any obligation to provide the attendees with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentation that may become apparent. No personhas been authorised to give any information or make any representations other than those contained in this presentation and, if given and/or made, such information or representations must not be relied upon as having been soauthorised. The information and opinions contained in this presentation are provided as at the date of this presentation.

In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Any graphs, tables or other information in this presentation demonstrating the historical performance of CMED or any other entity contained in thispresentation are intended only to illustrate past performance of such entities and are not necessarily indicative of future performance of CMED or such entities.

This presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person. Distribution of this presentation may be restricted or prohibitedby law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and CMED does not accept liability to any person in relation thereto.

FORWARD-LOOKING INFORMATION

This presentation contains “forward-looking information” within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future outlook and anticipated events or results and may includeinformation regarding our financial position, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, plans and objectives. Particularly, information regarding our expectations of future results,performance, achievements, prospects or opportunities or the markets in which we operates is forward-looking information. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as“plans”, “targets”, “expects” or “does not expect”, “an opportunity exists”, “outlook”, “prospects”, “strategy”, “intends”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”,“would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-lookinginformation. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

Forward-looking information contained in this presentation and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditionsand expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can beno assurance that the underlying opinions, estimates and assumptions will prove to be correct.

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information in this presentation, there may be other risk factors not presentlyknown to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurancethat such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information,which speaks only as of the date made. The forward-looking information contained in this presentation represents our expectations as of the date of this presentation or the date indicated, regardless of the time of delivery of thepresentation. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicablesecurities laws in Canada. All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements.

NON-IFRS MEASURES AND INDUSTRY METRICS

This presentation makes reference to certain non-IFRS measures including “EBITDA”, and to certain operating metrics in the industry. Non-IFRS measures including industry metrics do not have a standardized meaning prescribed by IFRSand are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding ofour results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. Please refer to the Prospectusfor further details on these non-IFRS measures including industry metrics, including relevant definitions and reconciliations.

3

Summary Overview

CanniMed Therapeutics Inc. (“CMED” or the “Company”) is a Canadian-based, international plant

biopharmaceutical company and a leader in the Canadian medical cannabis industry with 15 years’ of pharmaceutical cannabis cultivation experience, a state-of-the-art, GMP-compliant

production process including 281 points of quality control, and a world class research and

development platform, with a wide range of pharmaceutical-grade cannabis products.

CMED completed its initial public offering on December 29th 2016 for gross proceeds of $69.0MM and currently has an equity value of $275.1MM(1).

(1) As at March 17, 2017 closing price

4

Pharmaceutical Cannabis – The Opportunity is Significant

Legislative and political environments are becoming more favorable towards medical cannabis globally;

Canada is a leader

Commonly prescribed opioids have increased risk of addiction, overdose and mortality

Increasing health care costs demonstrate a strong need for alternative methods for pain management

Rapidly aging population seeking pain relief to maintain an active lifestyle and manage end-of-life conditions

5

Investor Highlights

Experienced LP with a 15 year history of growing medical cannabis

Pharmaceutical focus; GMP-compliant production process; investing in a clinical trial

Chronic pain costs more than $6 billion annually in Canada; issues with existing treatments create significant opportunity for cannabis products

Positioned to address significant market opportunity with baby boomers looking to maintain active lifestyles

Positive and accelerating EBITDA profile

Strong management and board with broad experience in cannabis, medical biotechnology, and pharmaceuticals

6

Record quarterly results in Q1 2017; revenue (+93.3% Y/Y), EBITDA (+$0.7MM Y/Y) and kg sold (+83.5% Y/Y)

Recent Developments

Entered into Canada’s First Exclusive Pharmacy Distribution Agreement for Medical Cannabis

Independent Laboratory Confirmed Products Free from Pesticides, Fungicides and Plant Growth Regulators

Agreement with CTT Pharmaceutical Holdings Inc. (“CTT”) to License its Orally Dissolvable Thin Film Wafer

7

100

1,000

10,000

100,000

1,000,000

10,000,000

2002 2005 2008 2011 2014 2017 2020 2023

Can

adia

n M

ed

ical

Can

nab

is U

sers

MMAR

MMPR/ACMPR

Trendline - MMAR

Trendline - MMPR/ACMPR

Medical Cannabis is a Growth Market in Canada

Medical Marijuana Registered Patients(1) MMPR Total Volume Sales(2)

Q/Q growth in Registered Patients

(1) Source: Health Canada and management estimates. Trend lines extrapolated by statistical software based on historical data.

(2) Rolling 12 months. Shown as at the end of the reporting period. Includes wholesale sales.

31% 18% 61%Q/Q growth in Volumes Q/Q growth in Oil

Market growth is surpassing Heath Canada projectionsCannabis oils have

accelerated market growth

Projected

Health Canada Projection:

450,000

MMPR Introduction

Sept 2016: 98,460

8

Physician Attitudes Shifting Towards Medical Cannabis

21%

52%

27%

(1) As reported by Legar Research Intelligence Group (2014 Survey) and Rogers Media (2016 Survey) through survey commissioned

by CanniMed Pharmaceuticals. Both surveys utilized the same questionnaire for comparability purposes. (2) Percentage of doctors

who have been approached by patients in the past 6 months

78%Doctors Approached(2)

Currently Prescribe

Interested in Prescribing

Will not Prescribe(under any circumstances)

2016(1)2014(1)

32%Properly Informed

12%

52%

36%

48%

31%

9

Broad Potential Benefits; Early Focus on Chronic Pain

(1) Various third-party studies. (2) As reported by Legar Research Intelligence Group through report commissioned in Sept 2016 by CanniMed.

• Various third-party studies suggest that medical cannabis has shown, or has potential to show, efficacy in the treatment of a large number of medical conditions

Alzheimer’s Disease Slows formation of amyloid plaques by blocking enzymes in the brainAnxiety Reduces agitationArthritis Reduces inflammation and painBrain injuries Reduces inflammation / swellingCancer (chemotherapy) Aids in pain management and enhances appetite; also shown to reduce

growth of some cancer cellsChronic nausea Reduces nauseaChronic pain Binds to receptors on nerves to relieve painEating disorders Stimulates appetiteEpilepsy Controls seizuresFibromyalgia Reduces inflammation and painGlaucoma Decrease pressure inside the eyeHepatitis C Reduces treatment side effects such as nausea and muscle achesHIV/AIDS Stimulates appetiteMigraines Reduces painMultiple Sclerosis Binds to receptors in the nerves and muscles to relieve painMuscle spasms Reduces inflammation and painParkinson’s Reduces pain and tremors and improves sleepPTSD Reduces flashbacks, agitation and nightmares

Prescribed Uses(2)Medical Condition Observed Medical Impact(1)

5%

5%

12%

19%

29%

33%

69%

69%

79%

79%

MultipleSclerosis

Other

Post-TraumaticStress Disorder

HIV/AIDS Pain

Anorexia

Nausea

Pallative

Cancer-RelatedPain

NeuropathicPain

Chronic Pain

10

17.5

21.7

2010 2014

$193.2

$219.1

2010 2015

• Canadians spent $219 billion on health care in 2015(1)

– 78%(2) of emergency department visits are due to pain

• One in five Canadian adults suffer from chronic pain(3)

• Chronic pain costs more than $6 billion annually(3)

– More than cancer, heart disease and HIV combined

– Productivity losses estimated to increase costs to more than $37 billion(3)

• Inadequate pain assessment and treatment is a growing problem in Canada(4)

• Opioids are commonly prescribed for chronic pain despite little evidence of long term efficacy(5) and an elevated risk of addiction and overdose– Canadian Federal Health Minister has called for a

reduction of opioid prescriptions

Pain Market is Large; Current Treatments are Inadequate

Heath Care Spending(1)

(1) National Health Expenditure Database. Canadian Institute for Health Information. (2) Canadian Pain Society. (3) Direct costs. Pain

Resource Centre, 2015: Pain in Canada Fact Sheet. (4) The Canadian Pain Society, 2011: Call to Action: The Need for a National Pain

Strategy for Canada. (5) Globe and Mail, October 2014; (6) Pain Physician Journal.

Opioid Prescriptions(6)

Medical cannabis may be a safe and effective alternative

11

• With an aging population, the incidence of chronic pain increases(2)

• Rate of opioid use as a pain reliever is highestamong seniors(3)

– 16% of seniors, as of 2013, use opioids(3)

• Baby boomers looking to manage pain and maintain an active lifestyle are a significant market opportunity for pharmaceutical-quality cannabis products

• New delivery mechanisms such as cannabis oils and gelcaps are ideally suited – More traditional forms – Easier to target symptoms and doses – Avoid stigmas associated with smoking

Baby Boomers Are a Key Target Market

Canadian Population Demographics(1)

29%

(1) Statistics Canada. (2) Pain Resource Centre, 2015: Pain in Canada Fact

Sheet. (3) In 2013; Canadian Centre on Substance Abuse, July 2015.

of the population

5,607,345

4,365,585

4,332,490

4,498,805

5,334,100

9,338,355

0 to 14 years

15 to 24 years

25 to 34 years

35 to 44 years

45 to 54 years

55 years and over

12

• Cannabis remains a Schedule I drug in the U.S.– 28 states and D.C. no longer prosecute– Change to Schedule II required for

cannabis to be declared fit for medical use

• DEA to allow increased supply of medical cannabis for research purposes

• CanniMed is in the process of applying to the DEA for a license– Production facility is expected to provide a

“first mover” advantage in providing pharmaceutical-grade medical cannabis in the US

• Several discussions for international distribution of the Company’s products ongoing– LOI with Creso Pharma

International Markets Offer Additional Opportunity

32%161 MM

29%89 MM

Population Aged 55 Years and Older

(1) National Conference of State Legislators updated to reflect the results of the 2016 US election. States that are categorized as “Legal

for Medical Use with Varying Limits on Use and Dosage” have different parameters for what patient conditions may be prescribed

medical cannabis, as well as the form of cannabis and delivery method. US federal law outlaws all non-research related use of cannabis.

(2) US Census Bureau; 2015. (3) European Union; Eurostat 2015. (4) Pew Research Centre

United States(2) European Union(3)

US State Cannabis Legislation(1)

~ 10,000 baby boomers will turn 65, every day, each year from 2011 to 2030(4)

Washington

Oregon

California

Montana

Wyoming

Colorado

New Mexico

Idaho

Nevada

Utah

Arizona

North Dakota

South Dakota

Nebraska

Kansas

Oklahoma

Texas

Minnesota

Iowa

MIssouri

Arkansas

Louisiana Florida

Michigan

Wisconsin

Illinois

Tennessee

Missis-

sippi Alabama

Georgia

South

Carolina

North

Carolina

Virginia

Kentucky

New

York

Pennsylvania

Ohio

Indiana West

Virgina

RI

Maine

VTNH

MA

CT

DEMD

NJ

Alaska

Hawaii

Legalized for Medical Use

Illegal

Legalized for Medical Use with

Varying Limits on Use and Dosage

13

• Canadian-based plant biopharmaceutical company and a leader in the Canadian medical cannabis industry

– 15 years’ pharmaceutical cannabis cultivation experience

– History as the sole supplier to Health Canada

– World class, international research and development platforms

• Focused on the development and production of pharmaceutical-grade cannabis products

– Good Manufacturing Practices(1) (“GMP”) compliant production with 281 points of quality control

– First Health Canada approved Phase IIA clinical trial

– Dosing, labeling and packaging similar to other pharmaceuticals

• A leader in the development of new delivery mechanisms with broader market appeal

– Cannabis oil gelcap production targeted for mid 2017

CanniMed Therapeutics – Pharmaceutical Focus

CMED is focused on becoming the supplier of choice in the medical community and with patients such as baby boomers who are looking for consistent, high quality treatment alternatives in forms that more closely align to traditional methods

(1) GMP are standards and procedures that pharmaceutical companies must adhere to in manufacturing their products in North America; part

of quality assurance that ensures that drugs are consistently produced and controlled to meet quality standards

14

• The Company continues to invest significant resources towards clinical trials focussed on validating medical cannabis as a safe and effective pain relief option

• $1 million invested in Health Canada-approved “CAPRI Trial”(1)

– First Phase II Health Canada approved clinical trial

– Randomized, double-blind, placebo controlled, proof-of-concept Phase IIA clinical trial

– Seeks to examine the varying ratios of THC and CBD to help determine whether high THC, high CBD, or a combination of the two, has the greatest impact on the treatment of osteoarthritis of the knee

• Answering important questions that physicians and other health care professionals have regarding dosing, as well as short term safety and efficacy relating to specific ratios of cannabinoids

Investing in Clinical Trials

(1) Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee

15

State-of-the-Art, GMP-Compliant Production Facilities

INSERT Saskatoon GRAPHIC

Saskatoon, Saskatchewan

• 97,000 sq. ft. above-ground production facility

• 30 large individual biosecure growth chambers

• 7,000 kg of dried herbal capacity per annum

• State-of-the-art, GMP-compliant production process

– 281 points of quality control

• Five separate Level 7 security compliant vaults

• “Seventh Generation” facility(1)

White Pine, Michigan

• 19,000 sq. ft of underground growth chambers currently under construction

• Supports BioProducts and BioPharm divisions

• Additional 35 square mile underground footprint

– Potential to support more than 50,000 kg of herbal capacity per annum

GMP

Standards

International Organization

for Standardization

(ISO)

Good Production Practices

(GPP)

Required under

ACMPR

Required for pharmaceutical

production

(1) Benefited from the technologies and innovations advanced over the course of seven distinct facility builds.

Only LP deemed by Health Canada to be compliant

16

CanniMed Product Offering – Herbal

• Pharmaceutical quality and branding promotes doctor confidence and supports more effective prescription dosages

– Identified by the percentage of THC and CBD they contain

– Each product is designed with specific benefits in mind to address each patient’s requirements

Colour and Name THC CBD

Purple 1·13 0.7% 13.0%

Red 4·10 4.0% 10.0%

Orange 9·9 9.0% 9.5%

Yellow 12·0 12.5% <0.5%

Green 15·5 15.0% 5.0%

Blue 17·1 17.0% 0.7%

Indigo 22·1 22.0% 0.7%

17

• Cannabis oils are the preferred product for patients reluctant to smoke herbal product

– Ideal for palliative care and hospitalized patients

– Significant sales acceleration since launching oils in January

• Gelcaps are ideally suited for baby boomers looking for a safe, reliable way to manage their chronic pain symptoms and maintain an active lifestyle

CanniMed Product Offering – Oils

Colour and Name THC (mg/ml) CBD (mg/ml) Total THC (mg) Total CBD (mg)

Purple 1·20 1.0 20.0 60 1,200

Orange 10·10 9.8 9.9 588 594

Blue 18·0 18.3 0.2 1,098 12

Cannabis Oil Gelcaps

Higher margin, value-added products with broader market appeal

Production to be initiated in

mid 2017

18

Growing Momentum

(1) Includes both dried herbal and oils

Patients Physicians

Total Dried Equivalents (KG)(1) Oil (KG Equivalent)

% of Revenue

8.2% 52.4%

19

• In 2014, the Company transitioned from the MMAR framework to the new MMPR/ACMPR regulatory regime

– Achieved positive adjusted EBITDA of $0.7MM in Q1 2017

– Continued to establish infrastructure and ramped up operations to anticipate growth

• Launching oils in 2016 has accelerated growth and expanded opportunities for new customer usage

– Introduction of pharmaceutical-grade gel caps anticipated to provide further growth & new market opportunities

Historical Financials

Revenue(1)(2) Gross Margin(1)(2)

(1) Financial results as of Q1 ending January 31, 2017; (2) Includes MMPR and ACMPR

(2)

30.5% Cannabis Oil Sales(1)

20

Strong Management Team and Board

Brent H. Zettl, B.S.A., President & CEO, Co-founder

• President of CanniMed since 1991• Spearheaded the development activities of the innovative underground

growth chambers• 2014 E&Y Entrepreneur of the Year for the Prairies Business-to-Consumer

category

John Knowles, CFO

• Over 30 years experience in senior executive and board roles in Canadaand internationally

• A Director of CanniMed for over eight years and past Chair of the Auditand Finance Board Committee

• Former VP, CFO of Hudbay Minerals Inc., Executive VP of Aur ResourcesInc., and CEO of LiCo Energy Metals Inc.

Larry Holbrook, Ph.D., Chief Research Officer

• Background includes Senior Research Scientist positions with extensiveand diverse agricultural biotechnology experience in both government andindustrial settings

• Over 20 years of experience in basic research and applications to geneticmodification of crop plants

• Author or co-author on 40 publications and books

Gulwant Bajwa, VP, Business Development and Regulatory Affairs

• Previously with Health Canada as a Senior Program Manager in formerBureau of Medical Cannabis and as a Policy Analyst in the IntellectualProperty and Technology Transfer office of Health Canada

• Five years as Director of Operations at JDS Uniphase Corporation

Donald Ching, LL.B, B.A. (Chairman)

• Director, Golden Opportunities Fund; Former President and CEO of SaskTel

Doug Banzet

• CFO and Director, Golden Opportunities Fund

Rob Duguid, B.B.A.

• Partner, PFM Capital; VP, Prairie Ventures Fund

Marianne Greer, Ph.D.

• Independent Pharmacist Consultant

Richard Hoyt, B.Sc.

• VP, Business Development, Mallinckrodt PLC

Dwayne L. Lashyn, B.Comm, C.A.

• VP, Quantico Capital Corp.

Bruce F. Mackler, Ph.D., J.D.

• Consultant in FDA, USDA and EPA Regulatory Processes

Brandon J. Price, Ph.D.

• Executive VP, Nascent Biotech; Co-founder, Biogenin

John L. Knowles, B.Comm, C.A.

• CFO, CanniMed Therapeutics Inc.

Brent Zettl

• President & CEO, CanniMed Therapeutics Inc.

Key Management Board of Directors

21